Cresset Asset Management’s RenaissanceRe RNR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$326K Sell
1,030
-8
-0.8% -$2.4K ﹤0.01% 1347
2026
Q1
$309K Buy
1,038
+168
+19% +$48.7K ﹤0.01% 1252
2025
Q4
$245K Sell
870
-78
-8% -$20.5K ﹤0.01% 1397
2025
Q3
$241K Buy
948
+23
+2% +$5.57K ﹤0.01% 1346
2025
Q2
$225K Sell
925
-633
-41% -$153K ﹤0.01% 1252
2025
Q1
$374K Buy
1,558
+213
+16% +$51.5K ﹤0.01% 1215
2024
Q4
$335K Sell
1,345
-742
-36% -$199K ﹤0.01% 1293
2024
Q3
$569K Buy
2,087
+478
+30% +$115K ﹤0.01% 1446
2024
Q2
$360K Buy
1,609
+590
+58% +$132K ﹤0.01% 1618
2024
Q1
$240K Sell
1,019
-54
-5% -$12K ﹤0.01% 1688
2023
Q4
$210K Buy
1,073
+59
+6% +$12.3K ﹤0.01% 1680
2023
Q3
$201K Buy
+1,014
New +$195K ﹤0.01% 1627
2019
Q2
Sell
-170
Closed -$24K 1427
2019
Q1
$24K Buy
170
+156
+1,114% +$21.8K ﹤0.01% 971
2018
Q4
$2K Buy
+14
New +$1.83K ﹤0.01% 1356

Other funds holding RNR

Cresset Asset Management's RNR Position: Q2 2026 in Review

Cresset Asset Management reduced its RenaissanceRe (RNR) stake by 0.77% in Q2 2026, selling an estimated $2.4K and leaving 1,030 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #1347.

Cresset Asset Management first reported a position in RNR in Q4 2018 and has held it in 14 quarters since. The position peaked at $569K in Q3 2024. 571 funds tracked by Wall St. Rank hold RNR as of Q2 2026.

  • Cresset Asset Management held 1,030 shares of RenaissanceRe worth $326K as of Q2 2026.
  • Cresset Asset Management sold 8 RenaissanceRe shares in Q2 2026, an estimated $2.4K.
  • RenaissanceRe made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1347 holding.
  • Cresset Asset Management first reported a position in RenaissanceRe in Q4 2018 and has held it in 14 quarters since.
  • Cresset Asset Management's RenaissanceRe position peaked at $569K in Q3 2024.
  • 571 funds tracked by Wall St. Rank held RenaissanceRe as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.